RAPT Therapeutics, Inc., a clinical-stage immunology-focused therapeutics company dedicated to discovering, developing, and commercializing oral small molecule therapies for patients in need of innovative treatments for inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel.
With his extensive experience and leadership in the healthcare, legal, and regulatory sectors, Listgarten will be instrumental in helping RAPT Therapeutics realize its mission and reach its full potential.
I am thrilled to welcome Michael to the RAPT leadership team. His extensive legal expertise and organizational leadership experience across various biopharmaceutical corporations will be invaluable as we move from development to potential commercialization. I’m confident that Michael will be a great asset to our team as we continue to grow.
Michael has a wealth of experience in both law and biopharmaceuticals, having spent more than 25 years helping businesses transition from late-stage clinical development to full-fledged commercial entities. He most recently served as Vice President of Healthcare Law & Chief Compliance Officer at Adamas Pharmaceuticals, where he provided legal support for the commercial and medical functions, advised on critical transactions, and ensured compliance with applicable laws and regulations.
Prior to Adamas, Michael was Vice President of Healthcare Law at Principia Biopharma. He also spent 16 years at Genentech, Inc., where he led a large team of attorneys in developing, manufacturing, distributing, and selling both large and small molecule therapies.
Before his career in biopharmaceuticals, Michael was an attorney at Covington & Burling LLP. Michael holds a J.D. and Masters of International Affairs from Columbia University, as well as a B.A. in Political Science from the University of Pennsylvania.
Michael is thrilled to be joining RAPT at such an exciting time. With two promising product candidates in development and the potential for pivotal trials in the near future, he is eager to contribute to the advancement of the pipeline and the growth of the company. His goal is to help ensure broad access to RAPT’s innovative oral therapies.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a groundbreaking clinical stage immunology-based therapeutics enterprise, dedicated to uncovering, developing and commercializing novel oral small molecule treatments for patients suffering from unmet needs in inflammatory diseases and oncology.
Leveraging its exclusive discovery and development engine, RAPT has designed highly selective small molecules that precisely target the critical immune drivers of these diseases.
Two of their pioneering drug candidates, RPT193 and FLX475, both focus on C-C motif chemokine receptor 4 (CCR4) and are developed for the treatment of inflammation and cancer respectively. Furthermore, the company is actively pursuing a vast array of targets in the discovery stage of development.